Last reviewed · How we verify
Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa
Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa is a Chemotherapy combination with erythropoiesis-stimulating agent Small molecule drug developed by GBG Forschungs GmbH. It is currently in Phase 3 development for Breast cancer (likely early-stage or metastatic, based on typical EC-T regimen use).
This combination regimen uses chemotherapy agents (epirubicin, cyclophosphamide, paclitaxel) to damage cancer cell DNA and inhibit microtubule function, while dabepoetin alfa stimulates red blood cell production to counteract chemotherapy-induced anemia.
This combination regimen uses chemotherapy agents (epirubicin, cyclophosphamide, paclitaxel) to damage cancer cell DNA and inhibit microtubule function, while dabepoetin alfa stimulates red blood cell production to counteract chemotherapy-induced anemia. Used for Breast cancer (likely early-stage or metastatic, based on typical EC-T regimen use).
At a glance
| Generic name | Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa |
|---|---|
| Sponsor | GBG Forschungs GmbH |
| Drug class | Chemotherapy combination with erythropoiesis-stimulating agent |
| Target | DNA (epirubicin, cyclophosphamide), microtubules (paclitaxel), erythropoietin receptor (dabepoetin alfa) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Epirubicin and cyclophosphamide are alkylating agents and topoisomerase inhibitors that cross-link DNA and prevent cancer cell replication. Paclitaxel stabilizes microtubules to disrupt cell division. Dabepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to increase hemoglobin levels in chemotherapy-induced anemia. This combination is designed to maximize cytotoxic effect while managing treatment-related side effects.
Approved indications
- Breast cancer (likely early-stage or metastatic, based on typical EC-T regimen use)
Common side effects
- Neutropenia
- Anemia
- Nausea and vomiting
- Alopecia
- Cardiotoxicity
- Peripheral neuropathy
- Thromboembolism (dabepoetin-associated)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa CI brief — competitive landscape report
- Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa updates RSS · CI watch RSS
- GBG Forschungs GmbH portfolio CI
Frequently asked questions about Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa
What is Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa?
How does Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa work?
What is Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa used for?
Who makes Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa?
What drug class is Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa in?
What development phase is Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa in?
What are the side effects of Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa?
What does Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa target?
Related
- Drug class: All Chemotherapy combination with erythropoiesis-stimulating agent drugs
- Target: All drugs targeting DNA (epirubicin, cyclophosphamide), microtubules (paclitaxel), erythropoietin receptor (dabepoetin alfa)
- Manufacturer: GBG Forschungs GmbH — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Breast cancer (likely early-stage or metastatic, based on typical EC-T regimen use)
- Compare: Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa vs similar drugs
- Pricing: Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa cost, discount & access